PHVS

Pharvaris NV

Add to Watchlist

Advanced Chart

22.220

-0.02(-0.090%)1D

Line

Candle

YTD

High

22.400

Open

22.260

VWAP

22.16

Vol

130.41K

Mkt Cap

1.42B

Low

21.760

Amount

2.89M

EV/EBITDA(TTM)

Total Shares

53.82M

1.19B

EV/OCF(TTM)

P/S(TTM)

Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

-0.682

-11.4%

-0.648

+1.25%

-0.647

-23.84%

Estimates Revision

Stock Price

Go Up

+4.64%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast PHVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHVS is 41.14 USD with a low forecast of 27.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

1 Hold

0 Sell

Strong Buy

Current: 22.220

Low

27.00

Averages

41.14

High

60.00

Current: 22.220

Low

27.00

Averages

41.14

High

60.00

H.C. Wainwright

NULL

Buy

initiated

$60

2025-10-15

Reason

H.C. Wainwright

Price Target

$60

2025-10-15

initiated

NULL

Buy

Reason

H.C. Wainwright initiated coverage of Pharvaris with a Buy rating and $60 price target. The company's lead asset deucrictibant is the only oral bradykinin B2 receptor antagonist in development across both on-demand and prophylaxis settings, the analyst tells investors in a research note. The firm says deucrictibant is positioned to set a new standard in hereditary angioedema on-demand and prophylaxis.

Citizens JMP

Outperform

NULL

downgrade

$55 -> $52

2025-08-13

Reason

Citizens JMP

Price Target

$55 -> $52

2025-08-13

downgrade

Outperform

NULL

Reason

Citizens JMP lowered the firm's price target on Pharvaris to $52 from $55 and keeps an Outperform rating on the shares. Pharvaris continues to execute on its pivotal hereditary angioedema programs with data from its pivotal RAPIDe-3 trial in acute HAE in Q4 and CHAPTER-3 data in HAE prophylaxis in the second half of 2026, the analyst tells investors in a research note. The firm is impressed with management's execution with the first Phase 3 data for deucrictibant for on-demand HAE treatment expected next quarter.

Guggenheim

initiated

$32

2025-06-11

Reason

Guggenheim

Price Target

$32

2025-06-11

initiated

Reason

Guggenheim initiated coverage of Pharvaris with a Buy rating and $32 price target.

Guggenheim

initiated

$32

2025-06-11

Reason

Guggenheim

Price Target

$32

2025-06-11

initiated

Reason

Cantor Fitzgerald

Overweight

downgrade

$28 -> $25

2025-05-14

Reason

Cantor Fitzgerald

Price Target

$28 -> $25

2025-05-14

downgrade

Overweight

Reason

Cantor Fitzgerald lowered the firm's price target on Pharvaris to $25 from $28 and keeps an Overweight rating on the shares. Pharvaris reported Q1 earnings and reiterated Phase 3 study readouts for on-demand treatment RAPIDe-3 in the first quarter of 2026, with target enrollment of 120 patients reached in March, and prophylactic treatment CHAPTER-3 in the second half of 2026, the analyst tells investors in a research note.

Wedbush

Outperform

maintain

$25 -> $27

2025-05-14

Reason

Wedbush

Price Target

$25 -> $27

2025-05-14

maintain

Outperform

Reason

Wedbush raised the firm's price target on Pharvaris to $27 from $25 and keeps an Outperform rating on the shares. The firm notes management reiterated key clinical milestones which includes potential readout timing for the RAPIDe-3 study of deucrictibant in Q1 2026, and CHAPTER-3 remains on track for the second half of 2026. Also notable in the update, Pharvaris secured tQT study waivers for both the XR and IR formulations, Wedbush adds.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Pharvaris NV (PHVS.O) is -7.29, compared to its 5-year average forward P/E of -6.86. For a more detailed relative valuation and DCF analysis to assess Pharvaris NV 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.86

Current PE

-7.29

Overvalued PE

-4.31

Undervalued PE

-9.42

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.45

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-1.54

Undervalued EV/EBITDA

-7.36

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.08

Current PS

19.28

Overvalued PS

1.36

Undervalued PS

-1.19